Pengaruh Penggunaan Amlodipine Terhadap Risiko Edema Perifer Pada Pasien Hipertensi: Tinjauan Literatur

Shofi Marsya, Hilfi Amalia, Januarini Maharani Putri, Jesika Olipia, Moch Akhdan, Rahayu Meilani, Heri Ridwan

Abstract


Amlodipine is a widely prescribed antihypertensive drug, but its side effect, peripheral edema, can cause discomfort and reduce patient compliance. The high prevalence of hypertension, including in Indonesia, makes understanding the balance between effectiveness and side effects crucial for both healthcare professionals and patients. The purpose of this literature review is to analyze the relationship between Amlodipine use and the risk of peripheral edema, including its mechanisms, risk factors, and clinical implications in therapeutic practice. The method used is a literature review with the PRISMA approach through a search of articles in the PubMed, Semantic Scholar, and Google Scholar databases using related keywords. Inclusion criteria included Indonesian and English-language articles published between 2015 and 2025 that discussed peripheral edema caused by Amlodipine. Of the 241 articles identified, only 5 articles met the criteria for further analysis. The analysis results showed that the incidence of peripheral edema ranged from 10% to 46.5%, with high doses and advanced age being the main risk factors. The main mechanism of edema is an imbalance in arteriolar and venular vasodilation that increases capillary hydrostatic pressure. Effective management strategies include combination with an ACE inhibitor/ARB, dose reduction, or the use of (S)-amlodipine as an alternative. In conclusion, amlodipine remains effective as an antihypertensive therapy, but peripheral edema is a common side effect and can impair quality of life and patient compliance. Therefore, monitoring risk factors and implementing appropriate management strategies are essential to optimize therapy.

Keywords


Kata Kunci: amlodipine, edema perifer, efek samping, hipertensi, kalsium antagonis

Full Text:

PDF

References


[1] W. H. Organization, “Hypertension fact sheet,” 2023. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/hypertension

[2] Riskesdas, “Laporan hasil riset kesehatan dasar 2023,” Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia, Jakarta, 2023.

[3] B. Williams, G. Mancia, W. Spiering, and et al., “2020 ESC/ESH Guidelines for the management of arterial hypertension,” Eur. Heart J., vol. 41, no. 6, pp. 1115–1205, 2020, doi: 10.1093/eurheartj/ehz839.

[4] C. Cicala and G. Maning, “Clinical implications of calcium channel blocker-induced edema: Pathophysiology and management strategies,” Cardiol. Rev., vol. 26, no. 3, pp. 117–123, 2018, doi: 10.1097/CRD.0000000000000205.

[5] M. J. Brown, R. L. Smith, and N. K. Patel, “Mechanisms of peripheral edema associated with calcium channel blockers,” J. Clin. Hypertens., vol. 21, no. 4, pp. 503–509, 2019, doi: 10.1111/jch.13578.

[6] & T. P. G. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., “Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement,” Moher, D., Lib. A., Tetzlaff, J., Altman, D. G., Prism. Group., vol. 6, no. 7, 2009.

[7] B. G. Katzung, Basic and clinical pharmacology, 14th ed. New York: McGraw-Hill Education, 2018.

[8] A. V Chobanian et al., “Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8),” JAMA, vol. 311, no. 5, pp. 507–520, 2014, doi: 10.1001/jama.2013.284427.

[9] M. R. Weir, “Calcium channel blockers in hypertension: Mechanisms of action and clinical applications,” Postgrad. Med., vol. 130, no. 5, pp. 523–533, 2018, doi: 10.1080/00325481.2018.1472817.

[10] P. Galappatthy, Y. C. Waniganayake, M. I. M. Sabeer, T. J. Wijethunga, G. K. S. Galappatthy, and R. A. I. Ekanayaka, “Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: A randomized double blind controlled clinical trial,” BMC Cardiovasc. Disord., vol. 16, p. 168, 2016, doi: 10.1186/s12872-016-0350-z.

[11] D. G. Harrison and G. C. Roush, “Pathophysiology and clinical implications of calcium channel blockers in hypertension,” Hypertens. Res., vol. 44, no. 2, pp. 89–98, 2021, doi: 10.1038/s41440-020-00555-0.

[12] H. S. Kamaruddin, N. Afifa, G. T. Tulak, and R. Masdin, “Hubungan usia, dosis, dan cara minum obat amlodipin terhadap risiko efek samping pada penderita hipertensi,” J. Sains dan Kesehat., vol. 7, no. 3, pp. 213–221, 2025, doi: 10.25026/jsk.v7i3.2460.

[13] D. A. Sica, “Calcium channel blocker–related peripheral edema: Can it be resolved?,” J. Clin. Hypertens., vol. 5, no. 4, pp. 291–294, 2003, doi: 10.1111/j.1524-6175.2003.02436.x.

[14] H. Makani, S. Bangalore, J. Romero, and F. H. Messerli, “Peripheral edema associated with calcium channel blockers: Incidence and withdrawal rate—A meta-analysis of randomized trials,” J. Hypertens., vol. 29, no. 7, pp. 1270–1280, 2011, doi: 10.1097/HJH.0b013e328346c506.

[15] F. H. Messerli and E. Grossman, “Calcium channel blocker–related peripheral edema: Can it be resolved?,” J. Clin. Hypertens., vol. 21, no. 9, pp. 1294–1299, 2019, doi: 10.1111/jch.13650.

[16] T. R. R. Tarapanjang, M. Riwu, C. O. Lada, and D. R. T. Manafe, “Korelasi faktor usia, cara minum, dan dosis obat amlodipin terhadap risiko efek samping pada penderita hipertensi,” Cendana Med. J., vol. 12, no. 2, pp. 23–33, 2024, doi: 10.35508/cmj.v%vi%i.15537.

[17] M. C. Acelajado and D. A. Calhoun, “Resistant hypertension and calcium channel blockers: Current insights,” J. Clin. Hypertens., vol. 20, no. 5, pp. 1010–1017, 2018, doi: 10.1111/jch.13240.

[18] M. Burnier and B. M. Egan, “Adherence in hypertension: A review of prevalence, risk factors, impact, and management,” Circ. Res., vol. 124, no. 7, pp. 1124–1140, 2019, doi: 10.1161/CIRCRESAHA.118.313220.




DOI: https://doi.org/10.52643/jbik.v15i4.7571

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Jurnal Bidang Ilmu Kesehatan

Flag Counter